Cardiol Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CAD 28.13 million compared to CAD 30.93 million a year ago. Basic loss per share from continuing operations was CAD 0.44 compared to CAD 0.49 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.4 CAD | -2.04% | -0.41% | +120.91% |
Apr. 22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
Apr. 01 | Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+120.91% | 122M | |
+1.64% | 42.75B | |
+47.70% | 41.61B | |
+12.15% | 41.34B | |
-8.83% | 26.59B | |
+6.62% | 25.49B | |
-23.36% | 18.12B | |
+30.00% | 12.24B | |
-2.42% | 11.76B | |
+8.06% | 11B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023